SGLT2 억제제 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "SGLT2 억제제" in Korean language version.

refsWebsite

Global rank Korean rank

31nih.gov

4^th place

29doi.org

2^nd place

3^rd place

14semanticscholar.org

11^th place

310^th place

8fda.gov

447^th place

433^rd place

3worldcat.org

5^th place

11^th place

3europa.eu

68^th place

145^th place

3drugs.com

399^th place

141^st place

2handle.net

102^nd place

307^th place

2web.archive.org

1^st place

1diabetesjournals.org

low place

6,992^nd place

1ovid.com

low place

1nmcd-journal.com

low place

1ulg.ac.be

7,875^th place

low place

1boehringer-ingelheim.com

low place

1yahoo.com

38^th place

105^th place

1astellas.com

low place

1clinicaltrials.gov

5,225^th place

4,327^th place

1globenewswire.com

2,614^th place

4,783^rd place

astellas.com

“Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan”. 2014년 1월 17일. 2015년 9월 23일에 원본 문서에서 보존된 문서. 2023년 4월 5일에 확인함.

boehringer-ingelheim.com

us.boehringer-ingelheim.com

“FDA approves Jardiance (empagliflozin) tablets for adults with type 2 diabetes”. Boehringer Ingelheim / Eli Lilly and Company. 2014년 8월 1일. 2014년 11월 5일에 원본 문서에서 보존된 문서. 2014년 11월 5일에 확인함.

clinicaltrials.gov

Clinical trial number NCT02531035 for "A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)" - ClinicalTrials.gov

diabetesjournals.org

“9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022”. 《diabetesjournals.org》. 2022년 9월 23일에 확인함.

doi.org

dx.doi.org

Shubrook, Jay; Baradar-Bokaie, Babak; Adkins, Sarah (2015). “Empagliflozin in the treatment of type 2 diabetes: Evidence to date”. 《Drug Design, Development and Therapy》 9: 5793–803. doi:10.2147/DDDT.S69926. PMC 4634822. PMID 26586935.
Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen (2018). “Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis”. 《European Journal of Preventive Cardiology》 25 (5): 495–502. doi:10.1177/2047487318755531. PMID 29372664. S2CID 3557967.
Bonora BM, Avogaro A, Fadini GP (2020). “Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence”. 《Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy》 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
Scheen, André J. (2014). “Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus”. 《Drugs》 75 (1): 33–59. doi:10.1007/s40265-014-0337-y. PMID 25488697. S2CID 9350259.
Haas, B.; Eckstein, N.; Pfeifer, V.; Mayer, P.; Hass, M D S. (2014). “Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin”. 《Nutrition & Diabetes》 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416.
Zheng, Sean L.; Roddick, Alistair J.; Aghar-Jaffar, Rochan; Shun-Shin, Matthew J.; Francis, Darrel; Oliver, Nick; Meeran, Karim (2018). “Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes”. 《JAMA》 319 (15): 1580–1591. doi:10.1001/jama.2018.3024. PMC 5933330. PMID 29677303.
Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. 《Heart Failure Reviews》 26 (3): 643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337. S2CID 226285893.
Zelniker TA, Wiviott SD, abatine MS (2019). “SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials”. 《The Lancet》 393 (10166): 31–39. doi:10.1016/S0140-6736(18)32590-X. PMID 30424892. S2CID 53277899.
Xu D, Chandler O, Xiao H (2021). “Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?”. 《Frontiers in Medicine》 8: 712671. doi:10.3389/fmed.2021.712671. PMC 8419219. PMID 34497814.
Hsia, Daniel S.; Grove, Owen; Cefalu, William T. (2016). “An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus”. 《Current Opinion in Endocrinology, Diabetes and Obesity》 24 (1): 73–79. doi:10.1097/MED.0000000000000311. PMC 6028052. PMID 27898586.
Isaacs, Michelle; Tonks, Katherine T.; Greenfield, Jerry R. (2017). “Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors”. 《Internal Medicine Journal》 47 (6): 701–704. doi:10.1111/imj.13442. PMID 28580740. S2CID 4091595.
Milder, D. A.; Milder, T. Y.; Kam, P. C. A. (August 2018). “Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations”. 《Anaesthesia》 (영어) 73 (8): 1008–1018. doi:10.1111/anae.14251. PMID 29529345.
Khouri, Charles; Cracowski, Jean-Luc; Roustit, Matthieu (2018). “SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?”. 《Diabetes, Obesity and Metabolism》 20 (6): 1531–1534. doi:10.1111/dom.13255. PMID 29430814. S2CID 3873882.
Bardia, Amit; Wai, Mabel; Fontes, Manuel L. (February 2019). “Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications”. 《Current Opinion in Anesthesiology》 (영어) 32 (1): 80–85. doi:10.1097/ACO.0000000000000674. PMID 30531609. S2CID 54471240.
Perlman, A.; Heyman, S. N.; Matok, I.; Stokar, J.; Muszkat, M.; Szalat, A. (2017년 12월 1일). “Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database”. 《Nutrition, Metabolism and Cardiovascular Diseases》 (영어) 27 (12): 1108–1113. doi:10.1016/j.numecd.2017.10.011. ISSN 0939-4753. PMID 29174031.
Neuen, Brendon L.; Young, Tamara; Heerspink, Hiddo J. L.; Neal, Bruce; Perkovic, Vlado; Billot, Laurent; Mahaffey, Kenneth W.; Charytan, David M.; Wheeler, David C.; Arnott, Clare; Bompoint, Severine; Levin, Adeera; Jardine, Meg J. (November 2019). “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. 《The Lancet. Diabetes & Endocrinology》 7 (11): 845–854. doi:10.1016/S2213-8587(19)30256-6. hdl:10044/1/79694. ISSN 2213-8595. PMID 31495651. S2CID 202003028.
Scheen, André J. (2014). “Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. 《Clinical Pharmacokinetics》 (Submitted manuscript) 53 (4): 295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. S2CID 5228432.
Bhartia, Mithun; Tahrani, Abd A.; Barnett, Anthony H. (2011). “SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment”. 《The Review of Diabetic Studies》 8 (3): 348–354. doi:10.1900/RDS.2011.8.348. PMC 3280669. PMID 22262072.
Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C.; Lacreta, Frank P.; Boulton, David W. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. 《Clinical Therapeutics》 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664.
Poole, Raewyn M.; Dungo, Rosselle T. (2014년 3월 26일). “Ipragliflozin: First Global Approval”. 《Drugs》 74 (5): 611–617. doi:10.1007/s40265-014-0204-x. PMID 24668021. S2CID 19837125.
Markham, Anthony; Elkinson, Shelley (2014). “Luseogliflozin: First Global Approval”. 《Drugs》 74 (8): 945–950. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
Da Silva, Paula Nogueira; Da Conceição, Raissa Alves; Do Couto Maia, Rodolfo; De Castro Barbosa, Maria Leticia (2018). “Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: A new antidiabetic drug class”. 《MedChemComm》 9 (8): 1273–1281. doi:10.1039/c8md00183a. PMC 6096352. PMID 30151080.
Poole, Raewyn M.; Prossler, Jennifer E. (2014). “Tofogliflozin: First Global Approval”. 《Drugs》 74 (8): 939–944. doi:10.1007/s40265-014-0229-1. PMID 24848755. S2CID 37021884.
Chao, E. C. (2014). “SGLT-2 Inhibitors: A New Mechanism for Glycemic Control”. 《Clinical Diabetes》 32 (1): 4–11. doi:10.2337/diaclin.32.1.4. PMC 4521423. PMID 26246672.
Anderson, Sarah L.; Marrs, Joel C. (2012). “Dapagliflozin for the Treatment of Type 2 Diabetes”. 《Annals of Pharmacotherapy》 46 (4): 590–598. doi:10.1345/aph.1Q538. PMID 22433611. S2CID 207264502.
Li, An-Rong; Zhang, Jian; Greenberg, Joanne; Lee, Taeweon; Liu, Jiwen (2011). “Discovery of non-glucoside SGLT2 inhibitors”. 《Bioorganic & Medicinal Chemistry Letters》 21 (8): 2472–2475. doi:10.1016/j.bmcl.2011.02.056. PMID 21398124.
Plosker, Greg L. (2012). “Dapagliflozin”. 《Drugs》 72 (17): 2289–2312. doi:10.2165/11209910-000000000-00000. PMID 23170914.
Madaan, Tushar; Akhtar, Mohd.; Najmi, Abul Kalam (2016). “Sodium glucose Co Transporter 2 (SGLT2) inhibitors: Current status and future perspective”. 《European Journal of Pharmaceutical Sciences》 93: 244–252. doi:10.1016/j.ejps.2016.08.025. PMID 27531551.
Packer M (2020). “Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors”. 《Circulation: Heart Failure》 13 (9): e007197. doi:10.1161/CIRCHEARTFAILURE.120.007197. PMID 32894987. S2CID 221540765.

drugs.com

“Jardiance”. 《drugs.com》. Drugs.com. 2014년 10월 31일에 확인함.
“Farxiga”. 《drugs.com》. Drugs.com. 2014년 10월 31일에 확인함.
“Invokana”. 《drugs.com》. Drugs.com. 2014년 10월 31일에 확인함.

europa.eu

ema.europa.eu

“SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information”. 《European Medicines Agency》. 2017년 5월 4일.
“Invokana EPAR”. 《European Medicines Agency (EMA)》. 2018년 10월 1일에 확인함.
“Forxiga EPAR”. 《European Medicines Agency (EMA)》. 2020년 2월 17일에 확인함.

fda.gov

“FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”. 《www.fda.gov》 (영어). Center for Drug Evaluation and Research. 2018년 9월 7일. Drug Safety and Availability쪽. 2019년 4월 16일에 확인함.
“FDA revises labels of SGLT2 inhibitors for diabetes to include warning”. 《U.S. Food and Drug Administration》. 2020년 3월 19일. 2020년 6월 6일에 확인함. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.
Research, Center for Drug Evaluation and (2019년 2월 9일). “FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)”. 《FDA》 (영어).
“Novel Drug Approvals for 2023”. 《Food and Drug Administration (FDA)》. U.S. Food and Drug Administration. 2023년 1월 20일.
“Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes - FDA” (PDF). 《Food and Drug Administration》.

accessdata.fda.gov

“Drug Approval Package: Invokana (canagliflozin) Tablets NDA #204042”. 《U.S. Food and Drug Administration (FDA)》. 1999년 12월 24일. 2020년 5월 5일에 확인함.
“Drug Approval Package: Farxiga (dapagliflozin) Tablets NDA #202293”. 《U.S. Food and Drug Administration (FDA)》. 1999년 12월 24일. 2020년 5월 5일에 확인함.
“Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) Tablets”. 《U.S. Food and Drug Administration (FDA)》. 2018년 3월 5일. 2020년 5월 6일에 확인함.

globenewswire.com

Sanofi (2019년 1월 17일). “Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes”. 《GlobeNewswire News Room》.

handle.net

hdl.handle.net

Neuen, Brendon L.; Young, Tamara; Heerspink, Hiddo J. L.; Neal, Bruce; Perkovic, Vlado; Billot, Laurent; Mahaffey, Kenneth W.; Charytan, David M.; Wheeler, David C.; Arnott, Clare; Bompoint, Severine; Levin, Adeera; Jardine, Meg J. (November 2019). “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. 《The Lancet. Diabetes & Endocrinology》 7 (11): 845–854. doi:10.1016/S2213-8587(19)30256-6. hdl:10044/1/79694. ISSN 2213-8595. PMID 31495651. S2CID 202003028.
Scheen, André J. (2014). “Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. 《Clinical Pharmacokinetics》 (Submitted manuscript) 53 (4): 295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. S2CID 5228432.

nih.gov

ncbi.nlm.nih.gov

Shubrook, Jay; Baradar-Bokaie, Babak; Adkins, Sarah (2015). “Empagliflozin in the treatment of type 2 diabetes: Evidence to date”. 《Drug Design, Development and Therapy》 9: 5793–803. doi:10.2147/DDDT.S69926. PMC 4634822. PMID 26586935.
Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen (2018). “Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis”. 《European Journal of Preventive Cardiology》 25 (5): 495–502. doi:10.1177/2047487318755531. PMID 29372664. S2CID 3557967.
Bonora BM, Avogaro A, Fadini GP (2020). “Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence”. 《Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy》 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
Scheen, André J. (2014). “Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus”. 《Drugs》 75 (1): 33–59. doi:10.1007/s40265-014-0337-y. PMID 25488697. S2CID 9350259.
Haas, B.; Eckstein, N.; Pfeifer, V.; Mayer, P.; Hass, M D S. (2014). “Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin”. 《Nutrition & Diabetes》 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416.
Zheng, Sean L.; Roddick, Alistair J.; Aghar-Jaffar, Rochan; Shun-Shin, Matthew J.; Francis, Darrel; Oliver, Nick; Meeran, Karim (2018). “Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes”. 《JAMA》 319 (15): 1580–1591. doi:10.1001/jama.2018.3024. PMC 5933330. PMID 29677303.
Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. 《Heart Failure Reviews》 26 (3): 643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337. S2CID 226285893.
Zelniker TA, Wiviott SD, abatine MS (2019). “SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials”. 《The Lancet》 393 (10166): 31–39. doi:10.1016/S0140-6736(18)32590-X. PMID 30424892. S2CID 53277899.
Xu D, Chandler O, Xiao H (2021). “Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?”. 《Frontiers in Medicine》 8: 712671. doi:10.3389/fmed.2021.712671. PMC 8419219. PMID 34497814.
Hsia, Daniel S.; Grove, Owen; Cefalu, William T. (2016). “An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus”. 《Current Opinion in Endocrinology, Diabetes and Obesity》 24 (1): 73–79. doi:10.1097/MED.0000000000000311. PMC 6028052. PMID 27898586.
Isaacs, Michelle; Tonks, Katherine T.; Greenfield, Jerry R. (2017). “Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors”. 《Internal Medicine Journal》 47 (6): 701–704. doi:10.1111/imj.13442. PMID 28580740. S2CID 4091595.
Milder, D. A.; Milder, T. Y.; Kam, P. C. A. (August 2018). “Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations”. 《Anaesthesia》 (영어) 73 (8): 1008–1018. doi:10.1111/anae.14251. PMID 29529345.
Khouri, Charles; Cracowski, Jean-Luc; Roustit, Matthieu (2018). “SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?”. 《Diabetes, Obesity and Metabolism》 20 (6): 1531–1534. doi:10.1111/dom.13255. PMID 29430814. S2CID 3873882.
Bardia, Amit; Wai, Mabel; Fontes, Manuel L. (February 2019). “Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications”. 《Current Opinion in Anesthesiology》 (영어) 32 (1): 80–85. doi:10.1097/ACO.0000000000000674. PMID 30531609. S2CID 54471240.
Perlman, A.; Heyman, S. N.; Matok, I.; Stokar, J.; Muszkat, M.; Szalat, A. (2017년 12월 1일). “Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database”. 《Nutrition, Metabolism and Cardiovascular Diseases》 (영어) 27 (12): 1108–1113. doi:10.1016/j.numecd.2017.10.011. ISSN 0939-4753. PMID 29174031.
Neuen, Brendon L.; Young, Tamara; Heerspink, Hiddo J. L.; Neal, Bruce; Perkovic, Vlado; Billot, Laurent; Mahaffey, Kenneth W.; Charytan, David M.; Wheeler, David C.; Arnott, Clare; Bompoint, Severine; Levin, Adeera; Jardine, Meg J. (November 2019). “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. 《The Lancet. Diabetes & Endocrinology》 7 (11): 845–854. doi:10.1016/S2213-8587(19)30256-6. hdl:10044/1/79694. ISSN 2213-8595. PMID 31495651. S2CID 202003028.
Scheen, André J. (2014). “Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. 《Clinical Pharmacokinetics》 (Submitted manuscript) 53 (4): 295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. S2CID 5228432.
Bhartia, Mithun; Tahrani, Abd A.; Barnett, Anthony H. (2011). “SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment”. 《The Review of Diabetic Studies》 8 (3): 348–354. doi:10.1900/RDS.2011.8.348. PMC 3280669. PMID 22262072.
Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C.; Lacreta, Frank P.; Boulton, David W. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. 《Clinical Therapeutics》 35 (8): 1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664.
Poole, Raewyn M.; Dungo, Rosselle T. (2014년 3월 26일). “Ipragliflozin: First Global Approval”. 《Drugs》 74 (5): 611–617. doi:10.1007/s40265-014-0204-x. PMID 24668021. S2CID 19837125.
Markham, Anthony; Elkinson, Shelley (2014). “Luseogliflozin: First Global Approval”. 《Drugs》 74 (8): 945–950. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
Da Silva, Paula Nogueira; Da Conceição, Raissa Alves; Do Couto Maia, Rodolfo; De Castro Barbosa, Maria Leticia (2018). “Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: A new antidiabetic drug class”. 《MedChemComm》 9 (8): 1273–1281. doi:10.1039/c8md00183a. PMC 6096352. PMID 30151080.
Poole, Raewyn M.; Prossler, Jennifer E. (2014). “Tofogliflozin: First Global Approval”. 《Drugs》 74 (8): 939–944. doi:10.1007/s40265-014-0229-1. PMID 24848755. S2CID 37021884.
Chao, E. C. (2014). “SGLT-2 Inhibitors: A New Mechanism for Glycemic Control”. 《Clinical Diabetes》 32 (1): 4–11. doi:10.2337/diaclin.32.1.4. PMC 4521423. PMID 26246672.
Anderson, Sarah L.; Marrs, Joel C. (2012). “Dapagliflozin for the Treatment of Type 2 Diabetes”. 《Annals of Pharmacotherapy》 46 (4): 590–598. doi:10.1345/aph.1Q538. PMID 22433611. S2CID 207264502.
Li, An-Rong; Zhang, Jian; Greenberg, Joanne; Lee, Taeweon; Liu, Jiwen (2011). “Discovery of non-glucoside SGLT2 inhibitors”. 《Bioorganic & Medicinal Chemistry Letters》 21 (8): 2472–2475. doi:10.1016/j.bmcl.2011.02.056. PMID 21398124.
Plosker, Greg L. (2012). “Dapagliflozin”. 《Drugs》 72 (17): 2289–2312. doi:10.2165/11209910-000000000-00000. PMID 23170914.
Madaan, Tushar; Akhtar, Mohd.; Najmi, Abul Kalam (2016). “Sodium glucose Co Transporter 2 (SGLT2) inhibitors: Current status and future perspective”. 《European Journal of Pharmaceutical Sciences》 93: 244–252. doi:10.1016/j.ejps.2016.08.025. PMID 27531551.
Packer M (2020). “Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors”. 《Circulation: Heart Failure》 13 (9): e007197. doi:10.1161/CIRCHEARTFAILURE.120.007197. PMID 32894987. S2CID 221540765.

pubmed.ncbi.nlm.nih.gov

Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. 《Heart Failure Reviews》 26 (3): 643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337. S2CID 226285893.
Neuen, Brendon L.; Young, Tamara; Heerspink, Hiddo J. L.; Neal, Bruce; Perkovic, Vlado; Billot, Laurent; Mahaffey, Kenneth W.; Charytan, David M.; Wheeler, David C.; Arnott, Clare; Bompoint, Severine; Levin, Adeera; Jardine, Meg J. (November 2019). “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. 《The Lancet. Diabetes & Endocrinology》 7 (11): 845–854. doi:10.1016/S2213-8587(19)30256-6. hdl:10044/1/79694. ISSN 2213-8595. PMID 31495651. S2CID 202003028.

nmcd-journal.com

Perlman, A.; Heyman, S. N.; Matok, I.; Stokar, J.; Muszkat, M.; Szalat, A. (2017년 12월 1일). “Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database”. 《Nutrition, Metabolism and Cardiovascular Diseases》 (영어) 27 (12): 1108–1113. doi:10.1016/j.numecd.2017.10.011. ISSN 0939-4753. PMID 29174031.

ovid.com

insights.ovid.com

Bardia, Amit; Wai, Mabel; Fontes, Manuel L. (February 2019). “Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications”. 《Current Opinion in Anesthesiology》 (영어) 32 (1): 80–85. doi:10.1097/ACO.0000000000000674. PMID 30531609. S2CID 54471240.

semanticscholar.org

api.semanticscholar.org

Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen (2018). “Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis”. 《European Journal of Preventive Cardiology》 25 (5): 495–502. doi:10.1177/2047487318755531. PMID 29372664. S2CID 3557967.
Scheen, André J. (2014). “Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus”. 《Drugs》 75 (1): 33–59. doi:10.1007/s40265-014-0337-y. PMID 25488697. S2CID 9350259.
Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. 《Heart Failure Reviews》 26 (3): 643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337. S2CID 226285893.
Zelniker TA, Wiviott SD, abatine MS (2019). “SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials”. 《The Lancet》 393 (10166): 31–39. doi:10.1016/S0140-6736(18)32590-X. PMID 30424892. S2CID 53277899.
Isaacs, Michelle; Tonks, Katherine T.; Greenfield, Jerry R. (2017). “Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors”. 《Internal Medicine Journal》 47 (6): 701–704. doi:10.1111/imj.13442. PMID 28580740. S2CID 4091595.
Khouri, Charles; Cracowski, Jean-Luc; Roustit, Matthieu (2018). “SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?”. 《Diabetes, Obesity and Metabolism》 20 (6): 1531–1534. doi:10.1111/dom.13255. PMID 29430814. S2CID 3873882.
Bardia, Amit; Wai, Mabel; Fontes, Manuel L. (February 2019). “Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications”. 《Current Opinion in Anesthesiology》 (영어) 32 (1): 80–85. doi:10.1097/ACO.0000000000000674. PMID 30531609. S2CID 54471240.
Neuen, Brendon L.; Young, Tamara; Heerspink, Hiddo J. L.; Neal, Bruce; Perkovic, Vlado; Billot, Laurent; Mahaffey, Kenneth W.; Charytan, David M.; Wheeler, David C.; Arnott, Clare; Bompoint, Severine; Levin, Adeera; Jardine, Meg J. (November 2019). “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. 《The Lancet. Diabetes & Endocrinology》 7 (11): 845–854. doi:10.1016/S2213-8587(19)30256-6. hdl:10044/1/79694. ISSN 2213-8595. PMID 31495651. S2CID 202003028.
Scheen, André J. (2014). “Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. 《Clinical Pharmacokinetics》 (Submitted manuscript) 53 (4): 295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. S2CID 5228432.
Poole, Raewyn M.; Dungo, Rosselle T. (2014년 3월 26일). “Ipragliflozin: First Global Approval”. 《Drugs》 74 (5): 611–617. doi:10.1007/s40265-014-0204-x. PMID 24668021. S2CID 19837125.
Markham, Anthony; Elkinson, Shelley (2014). “Luseogliflozin: First Global Approval”. 《Drugs》 74 (8): 945–950. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
Poole, Raewyn M.; Prossler, Jennifer E. (2014). “Tofogliflozin: First Global Approval”. 《Drugs》 74 (8): 939–944. doi:10.1007/s40265-014-0229-1. PMID 24848755. S2CID 37021884.
Anderson, Sarah L.; Marrs, Joel C. (2012). “Dapagliflozin for the Treatment of Type 2 Diabetes”. 《Annals of Pharmacotherapy》 46 (4): 590–598. doi:10.1345/aph.1Q538. PMID 22433611. S2CID 207264502.
Packer M (2020). “Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors”. 《Circulation: Heart Failure》 13 (9): e007197. doi:10.1161/CIRCHEARTFAILURE.120.007197. PMID 32894987. S2CID 221540765.

ulg.ac.be

orbi.ulg.ac.be

Scheen, André J. (2014). “Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. 《Clinical Pharmacokinetics》 (Submitted manuscript) 53 (4): 295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. S2CID 5228432.

web.archive.org

“FDA approves Jardiance (empagliflozin) tablets for adults with type 2 diabetes”. Boehringer Ingelheim / Eli Lilly and Company. 2014년 8월 1일. 2014년 11월 5일에 원본 문서에서 보존된 문서. 2014년 11월 5일에 확인함.
“Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan”. 2014년 1월 17일. 2015년 9월 23일에 원본 문서에서 보존된 문서. 2023년 4월 5일에 확인함.

worldcat.org

Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. 《Heart Failure Reviews》 26 (3): 643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337. S2CID 226285893.
Perlman, A.; Heyman, S. N.; Matok, I.; Stokar, J.; Muszkat, M.; Szalat, A. (2017년 12월 1일). “Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database”. 《Nutrition, Metabolism and Cardiovascular Diseases》 (영어) 27 (12): 1108–1113. doi:10.1016/j.numecd.2017.10.011. ISSN 0939-4753. PMID 29174031.
Neuen, Brendon L.; Young, Tamara; Heerspink, Hiddo J. L.; Neal, Bruce; Perkovic, Vlado; Billot, Laurent; Mahaffey, Kenneth W.; Charytan, David M.; Wheeler, David C.; Arnott, Clare; Bompoint, Severine; Levin, Adeera; Jardine, Meg J. (November 2019). “SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis”. 《The Lancet. Diabetes & Endocrinology》 7 (11): 845–854. doi:10.1016/S2213-8587(19)30256-6. hdl:10044/1/79694. ISSN 2213-8595. PMID 31495651. S2CID 202003028.

yahoo.com

finance.yahoo.com

“FDA Advisory Committee recommends approval of Jardiance (empagliflozin) for cardiovascular indication in 12-11 vote”. 《Yahoo! Finance》. 2016년 6월 28일. 2016년 8월 10일에 확인함.